Skip to main
NUVB
NUVB logo

Nuvation Bio (NUVB) Stock Forecast & Price Target

Nuvation Bio (NUVB) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 38%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Nuvation Bio Inc. demonstrates a promising outlook due to the robust efficacy of its lead product candidate, taletrectinib, which showed a confirmed overall response rate of 88.8% among TKI-naive patients and significant duration metrics, suggesting strong market potential in treating ROS1+ non-small cell lung cancer. The recent updates to clinical guidelines, favoring ROS1-targeted therapies, further enhance taletrectinib's expected market penetration, projected at 35% in the first-line setting, bolstered by the potential for ongoing revenue generation through additional pipeline candidates and out-licensing agreements in Asia. Financially, Nuvation Bio ended 2024 with $502.7 million in cash and marketable securities, positioning it well for continued operational activities and growth until reaching profitability.

Bears say

Nuvation Bio faces significant risks that contribute to a negative outlook on its stock, primarily stemming from potential negative clinical outcomes for its pipeline candidates, including taletrectinib, which is critical for its market positioning. The company's financials reflect a recent net loss of $0.15 per share for Q4 2024, aligning closely with estimates, while projections for a worse full-year 2025 net loss of $0.71 per share indicate deteriorating financial health. Additionally, uncertainties regarding regulatory approval and commercial uptake, compounded by competitive pressures and the risk of long-term dilution, further diminish investor confidence in the company's future profitability.

Nuvation Bio (NUVB) has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 38% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nuvation Bio and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nuvation Bio (NUVB) Forecast

Analysts have given Nuvation Bio (NUVB) a Buy based on their latest research and market trends.

According to 8 analysts, Nuvation Bio (NUVB) has a Buy consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.81, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.81, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nuvation Bio (NUVB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.